Chris Freeman

Chris Freeman is the current Chief Commercial Officer at Guardant Health. Prior to this, Chris was the Vice President, HIV Business Unit Head at Gilead Sciences from May 2011 to June 2021. In this role, Chris lead Gilead's $13B HIV treatment and prevention businesses and was responsible for the launch of Veklury (remdesivir) for emergency use authorization to treat COVID-19. Prior to Gilead, Chris was at Elan from October 2008 to May 2011 as the Director, Strategic Marketing & Alliance Management. In this role, Chris was the strategic marketing lead for Tysabri in Multiple Sclerosis and Crohn's Disease and the commercial lead for Alzheimer's pipeline products including ELND005 (P2) and Gamma (preIND). Chris was also responsible for ensuring the successful execution of partnered programs including the Alzheimer’s Immunotherapy Program (AIP) with Wyeth/Pfizer and J&J, Tysabri with Biogen Idec and ELND005 with Transition Therapeutics. Before Elan, Chris was at Genentech, Inc as the Group Manager, Oncology & Asthma Marketing from December 2001 to October 2008. Prior to Genentech, Chris served in the U.S. Army as a Captain in Armor from June 1996 to December 2001.

Chris Freeman has a BS in Chemistry and Life Sciences from the United States Military Academy at West Point. Chris also has an MA in Human Resources from Central Michigan University. Chris is currently a Doctoral Candidate in Marketing at Golden Gate University.

Chris Freeman reports to Helmy Eltoukhy, Co-CEO. Some individuals on their team include Bill Getty - SVP, Commercial Screening, Steven Collora - VP, Sales. Chris Freeman works with Michael Bell - CFO, Darya Chudova - SVP, Technology, and Craig Eagle - Chief Medical Officer.